成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Drug Resistance Updates >>article
Drug Resistance Updates

Drug Resistance Updates

IF: 15.8
Download PDF

Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer

Published:23 November 2024 DOI: 10.1016/j.drup.2024.101175
Li Yang, Aitian Li, Yi Zhang

Abstract

Aims

Immune checkpoint blockade therapy is not effective in most patients with non-small cell lung cancer (NSCLC) due to the immunosuppressive tumor microenvironment. Macrophages are key components of tumor-infiltrating immune cells and play a critical role in immunosuppression, which can be mediated by cell-intrinsic metabolism. This study aimed to evaluate whether macrophages regulate NSCLC progression through metabolic crosstalk with cancer cells and affect immunotherapy efficacy.

Methods

The macrophage landscape of NSCLC tissues were analyzed by single-cell sequencing and verified through flow cytometry and immunofluorescence. Multiplex assay, single-cell sequencing data, ELISA, immunofluorescence, and RNA-seq et al. were used to investigate and verify the mechanism of macrophage-mediated metabolic regulation on immunosuppression. The tumor-bearing model was established in C57BL/6?J mice to explore in vivo efficacy.

Results

We found that tumor tissue-derived macrophages exhibited an anti-inflammatory phenotype and had a prognostic value for NSCLC. NSCLC cell-secreted CXCL8 recruited macrophages from peritumor tissues to tumor sites and promoted programmed death-ligand 1 (PD-L1) expression by activating purine metabolism with increasing xanthine dehydrogenase and uric acid production. Moreover, purine metabolism-mediated macrophage immunosuppression was dependent on NLRP3/caspase-1/IL-1β signaling. Blockade of purine metabolism signaling enhanced anti-tumor immunity and the efficacy of anti-PD-L1 therapy.

Conclusions

Collectively, our findings reveal a key role of purine metabolism in macrophage immunosuppression and suggest that blockade of purine metabolism combined with immune checkpoint blockade could provide synergistic effects in NSCLC treatment.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Allopurinol 315-30-0 C5H4N4O 858 suppliers $5.00-$2285.00
Deoxyribonuclease 9003-98-9 NULL 289 suppliers $58.00-$2170.00
MCC950 210826-40-7 C20H24N2O5S 105 suppliers $58.00-$1416.00
FETUIN 9014-81-7 NULL 66 suppliers $37.07-$4380.00

Similar articles

IF:9.6

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Cancer treatment reviews Jordi Remon , Lizza E.L. Hendriks ,etc Published: 1 November 2020
IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Saudi Pharmaceutical Journal Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018
IF:12.7

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.

ACS Central Science Sabrina Baltschukat, Barbara Schacher Engstler,etc Published: 15 May 2019